

# Cezary A Szczylik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3604370/publications.pdf>

Version: 2024-02-01

140  
papers

28,146  
citations

57752

44  
h-index

11307

136  
g-index

141  
all docs

141  
docs citations

141  
times ranked

17897  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 115-124.	27.0	5,409
2	Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 125-134.	27.0	4,569
3	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	27.0	2,319
4	Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 1061-1068.	1.6	2,287
5	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. <i>Lancet, The</i> , 2007, 370, 2103-2111.	13.7	2,140
6	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3584-3590.	1.6	2,020
7	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. <i>Lancet, The</i> , 2011, 378, 1931-1939.	13.7	1,663
8	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3312-3318.	1.6	1,007
9	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. <i>Nature Medicine</i> , 2012, 18, 1254-1261.	30.7	721
10	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology, The</i> , 2009, 10, 757-763.	10.7	571
11	Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1280-1289.	1.6	463
12	A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. <i>European Journal of Cancer</i> , 2013, 49, 1287-1296.	2.8	402
13	Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3791-3799.	1.6	388
14	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 286-296.	10.7	239
15	Choosing the right cell line for renal cell cancer research. <i>Molecular Cancer</i> , 2016, 15, 83.	19.2	205
16	Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. <i>Clinical Cancer Research</i> , 2010, 16, 5539-5547.	7.0	184
17	Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. <i>Cancer</i> , 2009, 115, 61-67.	4.1	163
18	Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1454-1463.	6.3	131

#	ARTICLE	IF	CITATIONS
19	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. <i>Cancer</i> , 2011, 117, 501-509.	4.1	126
20	Treatment selection in metastatic renal cell carcinoma: expert consensus. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 327-337.	27.6	121
21	AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney. <i>Cancer</i> , 2012, 118, 6152-6161.	4.1	97
22	Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomised phase II study. <i>European Journal of Cancer</i> , 2008, 44, 2608-2614.	2.8	95
23	Three-dimensional cell culture model utilization in cancer stem cell research. <i>Biological Reviews</i> , 2017, 92, 1505-1520.	10.4	95
24	The role of the cell-cell interactions in cancer progression. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 283-296.	3.6	89
25	Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 613114.	4.8	88
26	Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET. <i>European Journal of Cancer</i> , 2010, 46, 2432-2440.	2.8	84
27	Wnt/ $\beta$ -catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. <i>Journal of Ovarian Research</i> , 2014, 7, 16.	3.0	73
28	Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 31-41.	7.4	73
29	The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. <i>Stem Cell Reviews and Reports</i> , 2015, 11, 919-943.	5.6	72
30	Prognostic Significance of Wnt-1, $\beta$ -catenin and E-cadherin Expression in Advanced Colorectal Carcinoma. <i>Pathology and Oncology Research</i> , 2011, 17, 955-963.	1.9	68
31	Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). <i>Current Signal Transduction Therapy</i> , 2014, 8, 219-228.	0.5	67
32	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. <i>European Journal of Cancer</i> , 2016, 69, 226-235.	2.8	65
33	The role of Tau protein in resistance to paclitaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 553-557.	2.3	60
34	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Journal of Cancer</i> , 2016, 65, 102-108.	2.8	60
35	Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e685-e693.	1.9	60
36	Prognostic Factors of Metastatic Renal Cell Carcinoma After Failure of Immunotherapy: New Paradigm From a Large Phase III Trial With Shark Cartilage Extract AE 941. <i>Journal of Urology</i> , 2007, 178, 1901-1905.	0.4	57

#	ARTICLE	IF	CITATIONS
37	Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. <i>Stem Cell Research and Therapy</i> , 2015, 6, 178.	5.5	57
38	Insulin and IGFs in renal cancer risk and progression. <i>Endocrine-Related Cancer</i> , 2015, 22, R253-R264.	3.1	54
39	The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1806, 82-95.	7.4	53
40	Insulin-like growth factor-1 signaling in renal cell carcinoma. <i>BMC Cancer</i> , 2016, 16, 453.	2.6	49
41	Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 25.	8.6	48
42	Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study. <i>Gynecologic Oncology</i> , 2011, 123, 33-36.	1.4	47
43	Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2010, 36, 16-23.	7.7	46
44	Interleukin-6 as an emerging regulator of renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 476-485.	1.6	45
45	The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory. <i>Current Pharmaceutical Design</i> , 2016, 22, 1756-1766.	1.9	43
46	Hormone signaling pathways as treatment targets in renal cell cancer (Review). <i>International Journal of Oncology</i> , 2016, 48, 2221-2235.	3.3	42
47	Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 18-25.	2.0	39
48	Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice. <i>Cancer Investigation</i> , 2010, 28, 856-864.	1.3	35
49	Vitamin D receptor gene polymorphisms in breast and renal cancer: Current state and future approaches. <i>International Journal of Oncology</i> , 2014, 44, 349-363.	3.3	35
50	Renin angiotensin system deregulation as renal cancer risk factor (Review). <i>Oncology Letters</i> , 2017, 14, 5059-5068.	1.8	35
51	Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 583.	2.6	34
52	Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2073.	4.1	33
53	Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. <i>Future Oncology</i> , 2014, 10, 1095-1111.	2.4	32
54	Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature. <i>International Journal of Molecular Medicine</i> , 2016, 38, 1887-1894.	4.0	32

#	ARTICLE	IF	CITATIONS
55	Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 323-337.	4.4	31
56	Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 457-464.	1.9	30
57	Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance. <i>Wspolczesna Onkologia</i> , 2018, 2018, 48-55.	1.4	30
58	Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model. <i>Cancer Research and Treatment</i> , 2018, 50, 103-110.	3.0	29
59	Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators. <i>Journal of Cell Communication and Signaling</i> , 2019, 13, 381-394.	3.4	29
60	Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells. <i>PLoS ONE</i> , 2016, 11, e0165718.	2.5	29
61	Cystatin C as a Parameter of Glomerular Filtration Rate in Patients with Ovarian Cancer. <i>Kidney and Blood Pressure Research</i> , 2010, 33, 360-367.	2.0	28
62	Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 371-378.	2.5	26
63	Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system. <i>OncoTargets and Therapy</i> , 2013, 6, 967.	2.0	25
64	Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression. <i>International Journal of Oncology</i> , 2014, 44, 1736-1744.	3.3	25
65	Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. <i>Future Oncology</i> , 2015, 11, 2267-2282.	2.4	25
66	Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F424-F436.	2.7	25
67	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. <i>Nature Reviews Urology</i> , 2019, 16, 655-673.	3.8	24
68	Management of pediatric head and neck rhabdomyosarcoma: A case-series of 36 patients. <i>Oncology Letters</i> , 2016, 12, 3555-3562.	1.8	22
69	Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. <i>Cell and Bioscience</i> , 2017, 7, 71.	4.8	22
70	External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model. <i>International Journal of Clinical Oncology</i> , 2019, 24, 526-532.	2.2	22
71	A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. <i>BJU International</i> , 2011, 107, 1190-1199.	2.5	21
72	Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma. <i>Current Signal Transduction Therapy</i> , 2014, 8, 210-218.	0.5	20

#	ARTICLE	IF	CITATIONS
73	Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2014, 4, 194.	2.8	19
74	Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. <i>Future Oncology</i> , 2017, 13, 31-49.	2.4	19
75	The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy. <i>Future Oncology</i> , 2014, 10, 2177-2187.	2.4	18
76	Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 1.	1.5	18
77	A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2012, 124, 205-209.	1.4	17
78	Metastasis-Initiating Cells in Renal Cancer. <i>Current Signal Transduction Therapy</i> , 2014, 8, 240-246.	0.5	17
79	Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. <i>Cytotechnology</i> , 2019, 71, 149-163.	1.6	17
80	Cardiovascular Comorbidities for Prediction of Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 468-476.	2.0	16
81	Ovarian cancer as a genetic disease. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 543.	3.0	16
82	Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. <i>Future Oncology</i> , 2015, 11, 17-26.	2.4	16
83	Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 215-220.	1.6	16
84	Colony, hanging drop, and methylcellulose three dimensional hypoxic growth optimization of renal cell carcinoma cell lines. <i>Cytotechnology</i> , 2017, 69, 565-578.	1.6	16
85	Functional significance of CD105-positive cells in papillary renal cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 21.	2.6	16
86	Colorectal cancer in the course of familial adenomatous polyposis syndrome (â€œde novoâ€œ-pathogenic) Tj ETQq0 0 0 rgBT /Overlock 1 <i>Science</i> , 2010, 2, 283-287.	0.9	15
87	Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors. <i>Anticancer Research</i> , 2018, 38, 359-365.	1.1	15
88	Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 159-174.	1.8	14
89	Metastatic colorectal cancer in the elderly: An overview of the systemic treatment modalities (Review). <i>Oncology Letters</i> , 2011, 2, 3-11.	1.8	13
90	Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. <i>Anti-Cancer Drugs</i> , 2013, 24, 431-440.	1.4	13

#	ARTICLE	IF	CITATIONS
91	Future perspectives for mTOR inhibitors in renal cell cancer treatment. <i>Future Oncology</i> , 2015, 11, 801-817.	2.4	13
92	Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 186-189.	0.9	12
93	Review Biology of renal tumour cancer stem cells applied in medicine. <i>Wspolczesna Onkologia</i> , 2015, 1A, 44-51.	1.4	12
94	Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer. <i>Oncology Reports</i> , 2016, 35, 1433-1442.	2.6	12
95	Triiodothyronine regulates cell growth and survival in renal cell cancer. <i>International Journal of Oncology</i> , 2016, 49, 1666-1678.	3.3	12
96	Role of WNT/ $\beta$ -Catenin Pathway as Potential Prognostic and Predictive Factors in Renal Cell Cancer Patients Treated With Everolimus in the Second and Subsequent Lines. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 257-265.	1.9	12
97	Metastatic renal cell carcinoma cells growing in 3D on polylysine or laminin present a stem-like phenotype and drug resistance. <i>Oncology Reports</i> , 2019, 42, 1878-1892.	2.6	12
98	Tracheal adenoid cystic carcinoma mimicking a thyroid tumor: A case report. <i>Oncology Letters</i> , 2014, 8, 1312-1316.	1.8	11
99	Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer. <i>Oncology Letters</i> , 2015, 10, 1423-1429.	1.8	11
100	K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. <i>Cancer Biology and Therapy</i> , 2012, 13, 1235-1243.	3.4	10
101	Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer. <i>Future Oncology</i> , 2014, 10, 2493-2508.	2.4	10
102	Renal cell carcinoma with intramyocardial metastases. <i>BMC Urology</i> , 2014, 14, 73.	1.4	10
103	Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. <i>Scientific Reports</i> , 2019, 9, 7754.	3.3	10
104	Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 143-148.	4.4	10
105	Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib. <i>Acta Oncologica</i> , 2009, 48, 921-925.	1.8	9
106	Molecular basis of carcinogenesis in diabetic patients (Review). <i>International Journal of Oncology</i> , 2015, 46, 1435-1443.	3.3	9
107	Thyroid Hormones as Renal Cell Cancer Regulators. <i>Journal of Signal Transduction</i> , 2016, 2016, 1-8.	2.0	8
108	Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer. <i>Oncology Letters</i> , 2016, 11, 1101-1104.	1.8	8



#	ARTICLE	IF	CITATIONS
109	The use of sunitinib in renal cell carcinoma: where are we now?. Expert Review of Anticancer Therapy, 2014, 14, 983-999.	2.4	7
110	Mitomycin C and High-Dose 5-Fluorouracil With Folinic Acid as a Therapeutic Option for Heavily Pretreated Patients With Metastatic Colorectal Cancer: Prospective Phase II Trial. Oncologist, 2014, 19, 356-357.	3.7	7
111	Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis. Future Oncology, 2015, 11, 2831-2840.	2.4	7
112	Dose Escalation and Pharmacokinetics Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 493-497.	1.3	6
113	Impaired glucose metabolism treatment and carcinogenesis. Oncology Letters, 2015, 10, 589-594.	1.8	6
114	Cystatin C as a predictor factor in patients with renal cell carcinoma treated by everolimus. Cancer Chemotherapy and Pharmacology, 2016, 78, 295-304.	2.3	6
115	Immune consequences of anti-angiogenic therapy in renal cell carcinoma. Wspolczesna Onkologia, 2018, 2018, 14-22.	1.4	6
116	Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets. Current Signal Transduction Therapy, 2014, 8, 203-209.	0.5	6
117	Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?. Archives of Medical Science, 2012, 8, 528-32.	0.9	6
118	Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. Journal of Cancer Research and Clinical Oncology, 2009, 135, 815-821.	2.5	5
119	Effects of cell-cell crosstalk on gene expression patterns in a cell model of renal cell carcinoma lung metastasis. International Journal of Oncology, 2017, 52, 768-786.	3.3	5
120	Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. Frontiers in Pharmacology, 2017, 8, 329.	3.5	5
121	Manageability of Acute Severe Heart Failure Complicated With Left Ventricular Thrombosis During Therapy for Breast Cancer. International Heart Journal, 2010, 51, 141-145.	1.0	4
122	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. Expert Opinion on Biological Therapy, 2017, 17, 151-162.	3.1	4
123	Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications. Future Oncology, 2017, 13, 593-602.	2.4	4
124	Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model. Cytotechnology, 2018, 70, 761-782.	1.6	4
125	Chemotherapy of pancreatic solid pseudopapillary carcinoma " A case report and a literature review. Cancer Treatment Communications, 2016, 7, 47-51.	0.4	3
126	Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells. Stem Cell Reviews and Reports, 2018, 14, 385-397.	5.6	3



#	ARTICLE	IF	CITATIONS
127	Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 283-292.	2.5	2
128	Malignant tumors in patients with end stage renal failure undergoing renal replacement therapy. <i>Wspolczesna Onkologia</i> , 2012, 5, 382-387.	1.4	2
129	Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2018, 35, 91.	2.5	2
130	Optimal chemotherapy treatment for patients with advanced colorectal cancer. <i>Wspolczesna Onkologia</i> , 2011, 1, 31-39.	1.4	1
131	Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma – hypoxia-induced factors. <i>Wspolczesna Onkologia</i> , 2012, 3, 250-253.	1.4	1
132	The Role of Diabetes in Molecular Pathogenesis of Cancer. <i>Current Signal Transduction Therapy</i> , 2015, 10, 10-16.	0.5	1
133	Axitinib in sequential therapy in metastatic renal cell carcinoma. <i>Wspolczesna Onkologia</i> , 2016, 5, 418-420.	1.4	1
134	Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway-targeted therapy and one prior mTOR inhibitor therapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 473-473.	1.6	1
135	Problems of diagnostic assessment in advanced pancreatic neuroendocrine neoplasm and treatment implications: a case report and literature review. <i>Nuclear Medicine Review</i> , 2016, 19, 54-57.	0.5	1
136	Bevacizumab plus irinotecan in treatment of recurrent brain gliomas. <i>Wspolczesna Onkologia</i> , 2010, 4, 253-258.	1.4	0
137	Efficacy and safety of surgical and chemoimmunotherapy combination treatment in patients with renal carcinoma and pulmonary metastases. <i>Wspolczesna Onkologia</i> , 2010, 1, 39-43.	1.4	0
138	M-TOR inhibitors in the treatment of advanced renal cell carcinoma. <i>Wspolczesna Onkologia</i> , 2011, 6, 343-349.	1.4	0
139	Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma – apoptosis-regulating factors. <i>Wspolczesna Onkologia</i> , 2012, 1, 90-93.	1.4	0
140	Okręgowy stół, 2013: zalecenia terapeutyczne w leczeniu systemowym rozlanego raka nerkowokomórkowego. <i>Nowotwory</i> , 2014, 64, 443-453.	0.3	0